PEGS 2013 - essential protein & antibody engineering summit
Cambridge Healthtech Institute is pleased to present its Ninth Annual PEGS, the essential protein engineering summit, being held this April 29-May 3, 2013 at the Seaport World Trade Center in Boston.
In addition to a new venue, the 2013 PEGS event offers six streams in the areas of protein & antibody engineering, oncology, expression, analytical, safety, and purification. These highly focused streams enable researchers to discuss and find solutions to challenges faced in the lab and hear research that has yet to be published. Conference short courses offer a primer or in-depth workshop on everything from phage and yeast display to immunogenicity and protein therapeutics. A biologics partnering forum will also be offered for both emerging companies with innovative technologies and established companies seeking collaborations.
Year after year, PEGS challenges attendees to evolve their thinking around the generation, characterization, and clinical application of proteins. Join over 1,200 of your colleagues this April in Boston to make your mark on the rapidly changing landscape of protein and antibody engineering.
PLENARY KEYNOTE PANEL
Tuesday, April 30, 2013 • 4:15 – 5:30 pm
Conventional vs. Non-Conventional Formats
Moderator: Janice Reichert, Ph.D., Editor-in-Chief, mAbs; Managing Director, Reichert Biotechnology Consulting LLC
With the explosion in the number of formats available, what are the potential benefits and risks to patients? This panel will discuss the realistic outlook and uncertainties with developing a diverse array of non-canonical antibodies in terms of immunogenicity, safety, competitive marketplace, commercial development, business strategies, regulatory approval, target validation and clinical development.
David Meininger, Ph.D., MBA, Executive Director, Molecular Discovery, Merck
Tillman Gerngross, Ph.D., CEO and Co-Founder, Adimab LLC; Professor, Bioengineering, Thayer School of Engineering, Dartmouth College
Trudi Veldman, Ph.D., Senior Director, Biologics Generation, AbbVie